Navigation Links
A sticky business -- how cancer cells become more 'gloopy' as they die

The viscosity, or 'gloopiness', of different parts of cancer cells increases dramatically when they are blasted with light-activated cancer drugs, according to new images that provide fundamental insights into how cancer cells die, published in Nature Chemistry today (15 March).

The images reveal the physical changes that occur inside cancer cells whilst they are dying as a result of Photodynamic Therapy (PDT). This cancer treatment uses light to activate a drug that creates a short-lived toxic type of oxygen, called singlet oxygen, which kills cancerous cells.

The research team behind the study says that revealing what happens to viscosity within a dying cancer cell is important because it helps give a better understanding of how cells function and which factors are important for controlling reactions inside cells. Ultimately this could help scientists design more efficient drugs for Photodynamic Therapy and other treatments.

The research is also of wider significance because these are the first ever real-time maps showing viscosity changing over a period of time inside a cell during a biologically important process like cell death.

Previous studies have shown that the viscosity of human cells and organs also changes in patients with diseases including diabetes and atherosclerosis, says lead author Dr Marina Kuimova from Imperial College London's Department of Chemistry.

She explains: "We're still not quite sure exactly what the relationship is between increased stickiness inside cells and disease, but we expect that the two are related."

"Knowing more about these changes, and being able to map them when they occur in all kinds of different scenarios, from dying cancer cells, to diseased blood cells, could help us to better understand how some diseases and their treatments affect cell and organ function."

Dr Kuimova and her colleagues were able to track viscosity as it changed inside live cancer cells thanks to a newly-developed Photodynamic Therapy drug, with unusual fluorescent properties. The drug, which is made of a molecule with a spinning component like a rotor, emits different wavelengths of light depending on the viscosity of its surroundings.

The changing wavelengths of light emitted during experiments, and captured over a period of 10 minutes, showed that once the PDT drug was activated, the level of viscosity inside the cell increased dramatically. The researchers suggest that this increasing 'gloopiness' is caused by the toxic oxygen molecules released into the cell. They think that increased levels of viscosity might even contribute directly to the cancer cell's further deterioration by slowing down vital communication and transport processes inside the cell.

Dr Stanley Botchway from the Science and Technology Facilities Council which worked in collaboration with Imperial College London on this research, said: "The huge viscosity we measured was surprising and it certainly gives a new insight into the change in cellular environment during cell death."

However, the researchers noted that as viscosity in the cancerous cell increases, the toxic oxygen molecule's mission to kill the cell is slowed down too.

Dr Kuimova explains: "It looks like whilst the increasing viscosity contributes to the cell's demise, these new 'sticky' cell conditions can slow the drug down too, so it's not as straightforward a relationship as it might first appear.

"More work is needed to better understand the complex interplay between viscosity and cell death. We hope to use our imaging technique to track changes in viscosity in other kinds of cells as they occur in real-time, to unlock some of the secrets of what goes on inside cells when they're functioning, malfunctioning or dying."


Contact: Danielle Reeves
Imperial College London

Related biology news :

1. As sticky as a gecko... but 10 times stronger!
2. Sticky questions tackled in gecko research
3. David Rose to present Howe School lecture on new technologies and business models, Jan. 29
4. Entrepreneurs wanted for NJIT workshops about how to launch a business
5. SAFRAN to Acquire Motorolas Biometrics Business
6. Fujitsu Scanners Selected as Editors Choice in Better Buys for Business 2008 Scan-to-File Guide
7. L-1 Identity Solutions Completes Acquisition of the ID Systems Business from Digimarc Corporation
8. Digimarc Board Approves $310 Million All-Cash Offer from L-1 Identity Solutions for Digimarcs ID Systems Business
9. Network science for eternal happiness and good business
10. DHS, business leaders discuss technology to protect US at Homeland Security conference
11. Adding up business and energy
Post Your Comments:
(Date:11/17/2015)... Mass. , Nov. 17, 2015 Pressure ... leader in the development and sale of broadly enabling, ... worldwide life sciences industry, today announced it has received ... its $5 million Private Placement (the "Offering"), increasing the ... $4,025,000.  One or more additional closings are expected in ...
(Date:11/12/2015)... , Nov. 12, 2015  Arxspan has entered ... MIT and Harvard for use of its ArxLab ... management tools. The partnership will support the institute,s ... and chemical research information internally and with external ... used for managing the Institute,s electronic laboratory notebook, ...
(Date:11/10/2015)... , Nov. 10, 2015  In ... on the basis of product, type, application, ... included in this report are consumables, services, ... report are safety biomarkers, efficacy biomarkers, and ... this report are diagnostics development, drug discovery ...
Breaking Biology News(10 mins):
(Date:11/30/2015)... , Nov. 30, 2015  AbbVie, is introducing ... that focuses on a daily routine for managing the ... their medication can affect the way the body absorbs ... to their a daily routine are important. The goal ... help patients better manage their hypothyroidism by establishing a ...
(Date:11/30/2015)... 2015  Northwest Biotherapeutics (NASDAQ: NWBO ) ("NW ... therapies for solid tumor cancers, announced today that the ... and the Company welcomes Neil Woodford,s call ... anonymous internet report on NW Bio.  The Company,s Board ... Powers stated, "We agree with Mr. Woodford that, ...
(Date:11/30/2015)... and PETACH TIKVAH, Israel , Nov. ... BCLI ), a leading developer of adult stem cell ... Brainstorm Cell Therapeutics Ltd., has been awarded an additional grant ... of the Chief Scientist (OCS). This grant, the second this ... 2015 activities to approximately $1.8 million (approximately NIS7 million).  ...
(Date:11/27/2015)... CHESTERFIELD, United Kingdom , Nov. 27, 2015 /PRNewswire/--  ... specialty biopharmaceutical company, announced today that it has closed ... systems (CMDS) business to Guerbet (GBT- NYSE Euronext) in ... CMDS operations encompassed four manufacturing facilities and a total ... nearly 75 in the St. Louis ...
Breaking Biology Technology: